This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generic-Drug Stocks Still Under the Weather

The negative reviews ranged from criticizing the lack of short-term revenue opportunities to Goldman Sachs' complaint about Barr's ability "to drive value from Pliva," the Croatian company it acquired after a bidding war in 2006.

"Although we find very little to like about the Pliva acquisition, we believe that most of the integration risk has now passed," adds Cowen's recent research report. But Cowen also says Barr "is about to enter what could be an exceedingly strong new U.S. product cycle."

Cowen expects a revenue boost from Barr's generic version of the Bayer oral contraceptive Yasmin. Barr's drug could reach the market in June or July. Given the complexities of patent challenges and regulatory approval for generics, Cowen says Barr could be the only seller of generic Yasmin through 2010.

The firm also says Barr will benefit from being the first seller of a generic copy of Adderall XR, the attention deficit hyperactivity disorder drug from Shire (SHPGY). The U.S. launch is expected in April 2009.

None of the analysts mentioned above own shares. Goldman Sachs has had a recent investment banking relationship with Barr. Merrill Lynch says it does, or seeks to do business, with companies mentioned in research reports.

Barr's purchase of Pliva was matched by Mylan's bigger acquisition of the generic-drug business of the German drug and chemical conglomerate Merck KGaA. Along with another deal giving Mylan a majority stake in India's Matrix, Mylan has created the world's third-largest generic-drugmaker and some indigestion for investors.

Mylan is now trying to sell Dey, a developer of drugs for respiratory ailments and allergies, which was part of the Merck deal. Mylan took a $385 million goodwill impairment charge for Dey, which contributed to a first-quarter operating loss of $371.5 million and a net loss of $443.9 million.

During the quarter, Mylan said the various Merck businesses, especially those outside the U.S., produced, on average, lower profit margins than Mylan's U.S. subsidiaries. Analysts say future risks include integrating the Merck businesses and producing greater value from the acquired products.

Mylan also cut its earnings projections not only for 2008 but also for 2009 and 2010. "The guidance for all three years is lower than what the investment community had expected," says a report by Credit Suisse, which has had a recent investment banking relationship.

"The bar has now been reset lower, but we believe it will take a few good quarters for investors to regain confidence in the name," the firm adds. Credit Suisse is keeping its outperform rating, and the firm is one of nine sell-siders with buy ratings, says Thomson Reuters. Four firms have hold recommendations.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WPI $85.73 0.00%
MYL $43.66 0.00%
NVS $93.27 0.00%
TEVA $60.06 0.00%
AAPL $110.38 0.00%


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs